Core Insights - Lexeo Therapeutics has announced a strategic partnership to develop therapies for genetic cardiac diseases using a novel non-viral RNA delivery platform, supported by an investment of up to $40 million from Perceptive Xontogeny Venture Funds and venBio Partners [1][2] - The genetic and precision cardiology market is projected to grow from over $13 billion in 2025 to nearly $40 billion by 2033, indicating significant opportunities for innovation in RNA therapeutics for cardiac diseases [3] Company Overview - Lexeo Therapeutics is a clinical stage genetic medicine company focused on pioneering treatments for cardiovascular diseases, with a portfolio that includes candidates targeting genetic causes of conditions such as Friedreich ataxia cardiomyopathy and plakophilin-2 arrhythmogenic cardiomyopathy [4] Partnership Details - The new entity formed through this partnership will focus on advancing RNA-based therapeutics via non-viral delivery for genetically mediated cardiac conditions, with Lexeo contributing its expertise, preclinical intellectual property, and technology [2][3] - Lexeo will receive a double-digit percentage equity position in the new entity, along with future milestone payments, royalties, and opt-in rights to certain programs [2]